
KYTX Stock Forecast & Price Target
KYTX Analyst Ratings
Bulls say
Kyverna Therapeutics Inc is making significant strides in the development of cell therapies targeting autoimmune diseases, with positive preliminary results from its KYV-101 treatment demonstrating notable improvements in various patient mobility metrics, including QMG and MG-ADL scores. The company has also reported encouraging outcomes in multiple sclerosis, with patients showing substantial reductions in oligoclonal bands, suggesting a potential decrease in disease progression. Additionally, the prospect of expanding its treatment platform with KYV-201 for multiple autoimmune diseases speaks to the long-term growth potential of Kyverna's innovative therapeutic approach.
Bears say
Kyverna Therapeutics reported a net loss of $0.80 per share for the third quarter of 2024, with projections indicating a full-year loss of $3.14 per share, underscoring significant financial challenges. The company’s clinical results for KYV-101, particularly in lupus nephritis, have been disappointing, raising concerns about the efficacy of DNA-based CAR-T therapies and their ability to achieve durable responses in autoimmune diseases. Additionally, the competitive landscape in multiple sclerosis presents further challenges, as patients have access to a variety of existing treatments, making it difficult for Kyverna's products to gain traction in the market.
This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KYTX Analyst Forecast & Price Prediction
Start investing in KYTX
Order type
Buy in
Order amount
Est. shares
0 shares